Phosphodiesterase inhibitors as a target for cognition enhancement in aging and alzheimer’s disease: A translational overview

Current Pharmaceutical Design

Volumn 21, Issue 3, 2015, Pages 317-331

  Heckman, P ^a   Wouters, C ^a   Prickaerts, J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

CAMP; CGMP; Dementia; Long term potentiation; Neurogenesis; PDE; Rolipram; Sildenafil

Indexed keywords

CILOSTAZOL; DONEPEZIL; MK 0952; PF 0447943; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE II INHIBITOR; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE IX; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PHOSPHODIESTERASE VI; PHOSPHODIESTERASE VII; PHOSPHODIESTERASE VIII; PHOSPHODIESTERASE X; PHOSPHODIESTERASE XI; SILDENAFIL; SPLEEN EXONUCLEASE; TADALAFIL; UNCLASSIFIED DRUG; VINPOCETINE;

AGING; ALZHEIMER DISEASE; ARTICLE; COGNITION; HUMAN; LONG TERM POTENTIATION; MEMORY; MEMORY DISORDER; MENTAL PERFORMANCE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SECOND MESSENGER; ANIMAL; CHEMISTRY; COGNITION DISORDERS; DRUG EFFECTS; ENZYMOLOGY; MOUSE; PATHOLOGY; TRANSLATIONAL RESEARCH;

AGING; ALZHEIMER DISEASE; ANIMALS; COGNITION; COGNITION DISORDERS; HUMANS; MICE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84925758089     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140826114601     Document Type: Article

References (166)

1. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580.
2. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75: 725-748.
3. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther, 2006; 109: 366-398.
4. Bender AT, Beavo JA. Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use. Pharmacol Rev 2006; 58: 488-520.
5. Francis SH, Blount MA, Corbin JD. Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions. Physiol Rev 2011; 91: 651-690.
6. Scott Bitner R. Cyclic AMP response element-binding protein (CREB) phosphorylation: A mechanistic marker in the development of memory enhancing Alzheimer’s disease therapeutics. Biochem Pharmacol 2012; 83: 705-714.
7. Lu Y-F, Kandel ER, Hawkins RD. Nitric Oxide Signaling Contributes to Late-Phase LTP and CREB Phosphorylation in the Hippocampus. J Neurosci 1999; 19: 10250-10261.
8. Bliss TVP, Collingridge GL. A synaptic model of memory: longterm potentiation in the hippocampus. Nature 1993; 361: 31-39.
9. Frey U, Huang YY, Kandel ER. Effects of cAMP Simulate a Late Stage of LTP in Hippocampal CA1 Neurons. Science 1993; 260: 1661-1664.
10. Reymann KG, Frey JU. The late maintenance of hippocampal LTP: Requirements, phases, ‘synaptic tagging’, ‘late-associativity’ and implications. Neuropharmacology 2007; 52: 24-40.
11. Izquierdo L, Barros D, Vianna MM, et al. Molecular Pharmacological Dissection of Short-and Long-Term Memory. Cell Mol Neurobiol 2002; 22: 269-287.
12. Sweatt JD. Toward a Molecular Explanation for Long-Term Potentiation. Learning & Memory 1999; 6: 399-416.
13. Arancio O, Kiebler M, Lee CJ, et al. Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons. Cell 1996; 87: 1025-35.
14. Taqatqeh F, Mergia E, Neitz A, Eysel UT, Koesling D, Mittmann T. More than a retrograde messenger: nitric oxide needs two cGMP pathways to induce hippocampal long-term potentiation. J Neurosci 2009; 29: 9344-50.
15. Impey S, Mark M, Villacres EC, Poser S, Chavkin C, Storm DR. Induction of CRE-mediated gene expression by stimuli that generate long-lasting LTP in area CA1 of the hippocampus. Neuron 1996; 16: 973-82.
16. Minichiello L. TrkB signalling pathways in LTP and learning. Nature Review Neuroscience 2009; 10: 850-860.
17. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nature Review Neuroscience 2005; 6: 603-614.
18. Lu Y, Christian K, Lu B. BDNF: A key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem 2008; 89: 312-323.
19. Gould E, Beylin A, Tanapat P, Reeves A, Shors TJ. Learning enhances adult neurogenesis in the hippocampal formation. Nature Neuroscience 1999; 2: 260-5.
20. Bruel-Jungerman E, Davis S, Rampon C, Laroche S. Long-term potentiation enhances neurogenesis in the adult dentate gyrus. J Neurosci 2006; 26: 5888-93.
21. Reneerkens OH, Rutten K, Steinbusch HM, Blokland A, Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 2009; 202: 419-443.
22. Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 1988; 31: 47-59.
23. Winters BD, Bussey TJ. Transient inactivation of perirhinal cortex disrupts encoding, retrieval, and consolidation of object recognition memory. J Neurosci 2005; 25: 52-61.
24. Mumby DG. Perspectives on object-recognition memory following hippocampal damage: lessons from studies in rats. Behav Brain Res 2001; 127: 159-81.
25. Boess FG, Hendrix M, van der Staay F, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004; 47: 1081-1092.
26. Ennaceur A, Neave N, Aggleton JP. Spontaneous object recognition and object location memory in rats: the effects of lesions in the cingulate cortices, the medial prefrontal cortex, the cingulum bundle and the fornix. Exp Brain Res 1997; 113: 509-519.
27. Itoh J, Ukai M, Kameyama T. Dynorphin A-(1-13) markedly improves scopolamine-induced impairment of spontaneous alternation performance in mice. European Journal of Pharmacology 1993; 236: 341-345.
28. Hiramatsu M, Inoue K. Des-tyrosine1 dynorphin A-(2-13) improves carbon monoxide-induced impairment of learning and memory in mice. Brain Res 2000; 859: 303-310.
29. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11: 47-60.
30. Barnes CA. Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J Comp Physiol A 1979; 93: 74-104.
31. Patil CS, Jain NK, Singh VP, Kulkarni SK. Differential effect of the PDE5 inhibitors, sildenafil and zaprinast, in aging-and lipopolysaccharide-induced cognitive dysfunction in mice. Drug Develop Res 2004; 63: 66-75.
32. Olton DS, Samuelson RJ. Remembrance of places passed: Spatial memory in rats. J Exp Psychol anim Behav Process 1976; 2: 97-116.
33. Sanders MJ, Wiltgen BJ, Fanselow MS. The place of the hippocampus in fear conditioning. Eur J Pharmacol 2003; 463: 217-223.
34. Cho CH, Cho DH, Seo MR, Juhnn YS. Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock. Exp Mol Med 2000; 32: 110-4.
35. Yan C, Bentley JK, Sonnenburg WK, Beavo JA. Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain. J Neurosci 1994; 14: 973-84.
36. Yan C, Zhao AZ, Bentley JK, Beavo JA. The calmodulindependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. Biol Chem 1996; 271: 25699-706.
37. Polli JW, Kincaid RL. Molecular cloning of DNA encoding a calmodulin-dependent phosphodiesterase enriched in striatum. Proceedings of the National Academy of Sciences 1992; 89: 11079-83.
38. DeNoble VJ. Vinpocetine enhances retrieval of a step-through passive avoidance response in rats. Pharmacol Biochem Behav 1987; 26: 183-6.
39. Deal watch: Intra-Cellular Therapies and Takeda to develop PDE1 inhibitors for schizophrenia. Nat Rev Drug Discov. 2011; 10(5):329. doi: 10.1038/nrd3438.
40. Deshmukh R, Sharma V, Mehan S, Sharma N, Bedi KL. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine--a PDE1 inhibitor. Eur J Pharmacol 2009; 620: 49-56.
41. Stephenson DT, Coskran TM, Kelly MP, et al. The distribution of phosphodiesterase 2A in the rat brain. Neuroscience 2012; 226: 145-155.
42. Van Staveren WC, Steinbusch HW, Markerink-Van Ittersum M, et al. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol 2003; 467: 566-80.
43. van Staveren WC, Steinbusch HW, Markerink-van Ittersum M, Behrends S, de Vente J. Species differences in the localization of cGMP-producing and NO-responsive elements in the mouse and rat hippocampus using cGMP immunocytochemistry. Eur J Neurosci 2004; 19: 2155-68.
44. Bolger GB, Rodgers L, Riggs M. Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene 1994; 149: 237-44.
45. Repaske DR, Corbin JG, Conti M, Goy MF. A cyclic GMPstimulated cyclic nucleotide phosphodiesterase gene is highly expressed in the limbic system of the rat brain. Neuroscience 1993; 56: 673-86.
46. Witzenrath M, Gutbier B, Schmeck B, et al. Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia. Crit Care Med 2009; 37: 584-90.
47. Genders AJ, Bradley EA, Rattigan S, Richards SM. cGMP phosphodiesterase inhibition improves the vascular and metabolic actions of insulin in skeletal muscle. Am J Phys 2011; 301: 7.
48. Domek-_opaci_ska K, Strosznajder JB. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 2008; 1216: 68-77.
49. Rutten K, Prickaerts J, Hendrix M, van der Staay FJ, Şik A, Blokland A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: Studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharmacol 2007; 558: 107-112.
50. Rutten K, Van Donkelaar EL, Ferrington L, et al. Phosphodiesterase Inhibitors Enhance Object Memory Independent of Cerebral Blood Flow and Glucose Utilization in Rats. Neuropsychopharmacology 2009; 34: 1914-1925.
51. Sierksma ASR, Rutten K, Sydlik S, et al. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Neuropharmacology 2013; 64: 124-136.
52. Degerman E, Belfrage P, Manganiello VC. Structure, Localization, and Regulation of cGMP-inhibited Phosphodiesterase (PDE3). J Biol Chem 1997; 272: 6823-6826.
53. Reinhardt RR, Chin E, Zhou J, et al. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J Clin Invest 1995; 95: 1528-38.
54. Hiramatsu M, Takiguchi O, Nishiyama A, Mori H. Cilostazol prevents amyloid_peptide25-35-induced memory impairment and oxidative stress in mice. Br J Pharmacol 2010; 161: 1899-1912.
55. Park SH, Kim JH, Bae SS, et al. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation. Biochem Biophys Res Com 2011; 408: 602-608.
56. Cherry JA, Davis RL. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol 1999; 407: 287-301.
57. Johansson EM, Reyes-Irisarri E, Mengod G. Comparison of cAMP-specific phosphodiesterase mRNAs distribution in mouse and rat brain. Neuroscience Letters 2012; 525: 1-6.
58. Pérez-Torres S, Miró X, Palacios JM, Cortés R, Puigdoménech P, Mengod G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography: Comparison with monkey and rat brain. J Chem Neuroanat 2000; 20: 349-374.
59. Cheng D, Ren J, Gillespie DG, Mi Z, Jackson EK. Regulation of 3’,5’-cAMP in preglomerular smooth muscle and endothelial cells from genetically hypertensive rats. Hypertension 2010; 56: 1096-101.
60. Richter W, Xie M, Scheitrum C, Krall J, Movsesian MA, Conti M. Conserved expression and functions of PDE4 in rodent and human heart. Basic Res Cardiol 2011; 106: 249-62.
61. Bach ME, Barad M, Son H, et al. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proceedings of the National Academy of Sciences 1999; 96: 5280-5285.
62. Comery TA, Martone RL, Aschmies S, et al. Acute_-Secretase Inhibition Improves Contextual Fear Conditioning in the Tg2576 Mouse Model of Alzheimer’s Disease. J Neurosci 2005; 25: 8898-8902.
63. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 2004; 114: 1624-1634.
64. Costa DA, Cracchiolo JR, Bachstetter AD, et al. Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms. Neurobiol Aging 2007; 28: 831-844.
65. Cheng YF, Wang C, Lin HB, et al. Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats. Psychopharmacology 2010; 212: 181-191.
66. Wang C, Yang XM, Zhuo YY, et al. The phosphodiesterase-4 inhibitor rolipram reverses Abeta-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats. Neuropsychopharmacology 2012; 15: 749-66.
67. Robichaud A, Savoie C, Stamatiou PB, et al. Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol 2002; 135: 113-118.
68. Burgin AB, Magnusson OT, Singh J, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nature Biotechnol 2010; 28: 63-70.
69. Bruno O, Fedele E, Prickaerts J, et al. GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. Br J Pharmacol 2011; 164: 2054-2063.
70. Paterno R, Faraci FM, Heistad DD. Role of Ca(2+)-dependent K+ channels in cerebral vasodilatation induced by increases in cyclic GMP and cyclic AMP in the rat. Stroke 1996; 27: 1603-7.
71. Giordano D, De Stefano ME, Citro G, Modica A, Giorgi M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta 2001; 1539: 16-27.
72. Kotera J, Fujishige K, Omori K. Immunohistochemical Localization of cGMP-binding cGMP-specific Phosphodiesterase (PDE5) in Rat Tissues. J Histochem Cytochem 2000; 48: 685-693.
73. Palmeri A, Privitera L, Giunta S, Loreto C, Puzzo D. Inhibition of phosphodiesterase-5 rescues age-related impairment of synaptic plasticity and memory. Behav Brain Res 2013; 240: 11-20.
74. Orejana L, Barros-Miñones L, Jordán J, Puerta E, Aguirre N. Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model. Neurobiol Aging 2012; 33: 625.e11-e20625.e20.
75. Puzzo D, Staniszewski A, Deng SX, et al. Phosphodiesterase 5 Inhibition Improves Synaptic Function, Memory, and Amyloid-β Load in an Alzheimer’s Disease Mouse Model. J Neurosci 2009; 29: 8075-8086.
76. Cuadrado-Tejedor M, Hervias I, Ricobaraza A, et al. Sildenafil restores cognitive function without affecting_-amyloid burden in a mouse model of Alzheimer’s disease. Br J Pharmacol 2011; 164: 2029-2041.
77. Zhang J, Guo J, Zhao X, et al. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav Brain Res 2013; 250: 230-37.
78. Austin SA, Santhanam AV, Katusic ZS. Endothelial Nitric Oxide Modulates Expression and Processing of Amyloid Precursor Protein. Circul Res 2010; 107: 1498-1502.
79. Kwak YD, Wang R, Li J, Zhang Y-W, Xu H, Liao FF. Differential regulation of BACE1 expression by oxidative and nitrosative signals. Mol Neurodegeneration 2011; 6: 17.
80. Prickaerts J, Şık A, van Staveren WCG, et al. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem Int 2004; 45: 915-928.
81. García-Barroso C, Ricobaraza A, Pascual-Lucas M, et al. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology 2013; 64: 114-123.
82. Kruuse C, Gupta S, Nilsson E, Kruse L, Edvinsson L. Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries. Eur J Pharmacol 2012; 674: 345-51.
83. Zhang R, Wang Y, Zhang L, et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 2002; 33: 2675-80.
84. Miro X, Perez-Torres S, Palacios JM, Puigdomenech P, Mengod G. Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse 2001; 40: 201-14.
85. Perez-Gonzalez R, Pascual C, Antequera D, et al. Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer’s disease. Neurobiol Aging 2003: 1-13.
86. Kruse LS, Moller M, Kruuse C. Distribution of PDE8A in the nervous system of the Sprague-Dawley rat. J Chem Neuroanat 2011; 42: 184-91.
87. Kobayashi T, Gamanuma M, Sasaki T, et al. Molecular comparison of rat cyclic nucleotide phosphodiesterase 8 family: unique expression of PDE8B in rat brain. Gene 2003; 319: 21-31.
88. DeNinno MP, Wright SW, Visser MS, et al. 1,5-Substituted nipecotic amides: selective PDE8 inhibitors displaying diastereomer-dependent microsomal stability. Bioorg Med Chem 2011; 21: 3095-8.
89. van Staveren WCG, Glick J, Markerink-van Ittersum M, et al. Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J Neurocytol 2002; 31: 729-41.
90. Andreeva SG, Dikkes P, Epstein PM, Rosenberg PA. Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain. J Neurosci 2001; 21: 9068-76.
91. Soderling SH, Bayuga SJ, Beavo JA. Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases. J Biol Chem 1998; 273: 15553-8.
92. van der Staay FJ, Rutten K, Bärfacker L, et al. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 2008; 55: 908-18.
93. Hutson PH, Finger EN, Magliaro BC, et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2Hpyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 2011; 61: 665-76.
94. Kleiman RJ, Chapin DS, Christoffersen C, et al. Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo. J Pharmacol Exp Ther 2012; 341: 396-409.
95. Vardigan JD, Converso A, Hutson PH, Uslaner JM. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task. J Neurogenet 2011; 25: 120-6.
96. Kleiman RJ, Lanz TA, Finley JE, et al. Dendritic spine density deficits in the hippocampal CA1 region of young Tg2576 mice are ameliorated with the PDE9A inhibitor PF-04447943. Alzheimer’s Dementia 2010; 6:5.
97. Seeger TF, Bartlett B, Coskran TM, et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res 2003; 985: 113-26.
98. Fujishige K, Kotera J, Omori K. Striatum-and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 1999; 266: 1118-27.
99. Soderling SH, Bayuga SJ, Beavo JA. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proceedings of the National Academy of Sciences 1999; 96: 7071-6.
100. Schmidt CJ, Chapin DS, Cianfrogna J, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Therap 2008; 325: 681-90.
101. Reneerkens OA, Sambeth A, Blokland A, Prickaerts J. PDE2 and PDE10, but not PDE5, inhibition affect basic auditory information processing in rats. Behav Brain Res 2013; 17: 00285-4.
102. Reneerkens OA, Rutten K, Bollen E, et al. Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behav Brain Res 2013; 236: 16-22.
103. Rodefer JS, Saland SK, Eckrich SJ. Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats. Neuropharmacology 2012; 62: 1182-90.
104. Grauer SM, Pulito VL, Navarra RL, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Therap 2009; 331: 574-90.
105. Kelly MP, Logue SF, Brennan J, et al. Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes. Proceedings of the National Academy of Sciences 2010; 107: 8457-62.
106. Domek-_opaci_ska K, Strosznajder J. Cyclic GMP and Nitric Oxide Synthase in Aging and Alzheimer’s Disease. Mol Neurobiol 2010; 41: 129-137.
107. Blokland A, Schreiber R, Prickaerts J. Improving memory: a role for phosphodiesterases. Cur Pharm Design 2006; 12: 2511-23.
108. Jancic D, Lopez de Armentia M, Valor LM, Olivares R, Barco A. Inhibition of cAMP response element-binding protein reduces neuronal excitability and plasticity, and triggers neurodegeneration. Cereb Cortex 2009; 19: 2535-47.
109. Chen RW, Williams AJ, Liao Z, Yao C, Tortella FC, Dave JR. Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. Neuroscience Letters 2007; 418: 165-9.
110. Lu YF, Hawkins RD. Ryanodine receptors contribute to cGMPinduced late-phase LTP and CREB phosphorylation in the hippocampus. Journal of Neurophysiology, 2002; 88: 1270-8.
111. Saura CA, Valero J. The role of CREB signaling in Alzheimer’s disease and other cognitive disorders. Rev Neurosci 2011; 22: 153-69.
112. Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010; 59: 367-74.
113. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00719953 (NLM Identifier: NCT00719953). [Accessed 11 December 2013].
114. Subhan Z, Hindmarch I. Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur J Clin Pharmacol 1985; 28: 567-71.
115. Richter Y, Herzog Y, Eyal I, Cohen T. Cognitex supplementation in elderly adults with memory complaints: an uncontrolled open label trial. J Diet Suppl 2011; 8: 158-68.
116. Thal LJ, Salmon DP, Lasker B, Bower D, Klauber MR. The safety and lack of efficacy of vinpocetine in Alzheimer’s disease. J Am Geriatr Soc 1989; 37: 515-20.
117. Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev 2003; 1.
118. Reyes-Irisarri E, Markerink-Van Ittersum M, Mengod G, De Vente J. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer’s disease human brains. Eur J Neurosci 2007; 25: 3332-3338.
119. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00041054 (NLM Identifier: NCT00041054). [Accessed 11 December 2013].
120. ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00078910 (NLM Identifier: NCT00078910).[Accessed 11 December 2013].
121. ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00026468 (NLM Identifier: NCT00026468).[Accessed 11 December 2013].
122. ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00037609 (NLM Identifier: NCT00037609).[Accessed 11 December 2013].
123. ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00216749 (NLM Identifier: NCT00216749).[Accessed 11 December 2013].
124. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00234065 (NLM Identifier: NCT00234065).[Accessed 11 December 2013].
125. Shirayama Y, Konishi T, Hashimoto K. Effects of add-on cilostazol on cognition in patients with schizophrenia: an open-label pilot trial. J Clin Psychopharmacol 2011; 31: 659-661.
126. Arai H, Takahashi T. A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study. Am J Geriatr Psychiatry 2009; 17: 353-4.
127. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT01409564 (NLM Identifier: NCT01409564). [Accessed 11 December 2013].
128. Sakurai H, Hanyu H, Sato T, et al.Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer’s disease and cerebrovascular disease: a pilot study. Geriatr Gerontol Int 2013; 13: 90-7.
129. Kai Y, Watanabe M, Morioka M, et al. Cilostazol improves symptomatic intracranial artery stenosis-Evaluation of cerebral blood flow with single photon emission computed tomography. Surg Neurol Int 2011; 2: 8.
130. Mochizuki Y, Oishi M, Mizutani T. Effects of cilostazol on cerebral blood flow, P300, and serum lipid levels in the chronic stage of cerebral infarction. J Stroke Cerebrovasc Dis 2001; 10: 63-9.
131. Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 2004; 24: 1352-8.
132. Braun NN, Reutiman TJ, Lee S, Folsom TD, Fatemi SH. Expression of phosphodiesterase 4 is altered in the brains of subjects with autism. Neuroreport 2007; 18: 1841-4.
133. McLachlan CS, Chen ML, Lynex CN, Goh DL, Brenner S, Tay SK. Changes in PDE4D isoforms in the hippocampus of a patient with advanced Alzheimer disease. Arch Neurol 2007;64(3):456-7.
134. Esposito K, Reierson GW, Luo HR, Wu GS, Licinio J, Wong ML. Phosphodiesterase genes and antidepressant treatment response: a review. Ann Med 2009; 41: 177-85.
135. Fleischhacker WW, Hinterhuber H, Bauer H, et al.A multicenter double-blind study of three different doses of the new cAMPphosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 1992; 26: 59-64.
136. ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00362024 (NLM Identifier: NCT00362024).[Accessed 11 December 2013].
137. ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT01433666 (NLM Identifier: NCT01433666).[Accessed 11 December 2013].
138. Izquierdo JL, Aparicio J. Roflumilast for COPD. Drugs Today 2010; 46: 823-31.
139. Puhan M. Phosphodiesterase type 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Systematic Reviews 11 2011; ED000028.
140. ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00723177 (NLM Identifier: NCT00723177).[Accessed 11 December 2013].
141. Puzzo D, Sapienza S, Arancio O, Palmeri A. Role of phosphodiesterase 5 in synaptic plasticity and memory. J Neuropsych Disease Treatment 2008; 4: 371-87.
142. ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00125918 (NLM Identifier: NCT00125918).[Accessed 11 December 2013].
143. ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00718952 (NLM Identifier: NCT00718952).[Accessed 11 December 2013].
144. ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00452582 (NLM Identifier: NCT00452582).[Accessed 11 December 2013].
145. Grass H, Klotz T, Fathian-Sabet B, Berghaus G, Engelmann U, Kaferstein H. Sildenafil (Viagra): is there an influence on psychological performance? Int Urol Nephrol 2001; 32: 409-12.
146. Schultheiss D, Muller SV, Nager W, et al.Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World J Urol 2001; 19: 46-50.
147. Goff DC, Cather C, Freudenreich O, et al.A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology 2009; 202: 411-7.
148. Shim YS, Pae CU, Kim SW, Kim HW, Kim JC, Koh JS. Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: a pilot study. Int J Imp Res 2011; 23: 109-14.
149. Reneerkens OA, Sambeth A, Van Duinen MA, Blokland A, Steinbusch HW, Prickaerts J. The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans. Psychopharmacology 2013; 225: 303-12.
150. Reneerkens O, Sambeth A, Ramaekers J, Steinbusch H, Blokland A, Prickaerts J. The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral-electroencephalography study. J Psychopharmacology 2013; 20: 20.
151. Arnavaz A, Aurich A, Weissenborn K, Hartmann U, Emrich HM, Schneider U. Effect of sildenafil (Viagra) on cerebral blood flow velocity: a pilot study. Psychiatry Res 2003; 122: 207-9.
152. Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003; 126: 241-7.
153. Kruuse C, Hansen AE, Larsson HB, Lauritzen M, Rostrup E. Cerebral haemodynamic response or excitability is not affected by sildenafil. J Cereb Blood Flow Metab 2009; 29: 830-9.
154. Pérez-Torres S, Cortés R, Tolnay M, Probst A, Palacios JM, Mengod G. Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer’s disease brains examined by in situ hybridization. Exp Neurol 2003; 182: 322-334.
155. Wang P, Wu P, Egan RW, Billah MM. Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5): Differential tissue distribution and subcellular localization of PDE9A variants. Gene 2003; 314: 15-27.
156. Rentero C, Monfort A, Puigdomènech P. Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene. Biochem Biophys Res Commun 2003; 301: 686-692.
157. ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00930059 (NLM Identifier: NCT00930059).[Accessed 11 December 2013].
158. Schwam E, Evans R, Nicholas T, et al.PF-04447943: a phase II controlled clinical trial of a selective PDE9A inhibitor in Alzheimer’s disease. Alzheimer’s Dementia 2011; 7:6.
159. Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Current opinion in investigational drugs 2007; 8: 54-9.
160. ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00570063 (NLM Identifier: NCT00570063).[Accessed 11 December 2013].
161. Krause W, Kuhne G. Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica 1988; 18: 561-71.
162. Reneerkens OA, Rutten K, Akkerman S, et al.Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms. Neurobiol Learn Mem 2012; 97: 370-9.
163. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011; 163: 53-67.
164. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 1986; 19: 253-62.
165. Gurney ME, Burgin AB, Magnusson OT, Stewart LJ. Small molecule allosteric modulators of phosphodiesterase 4. Handbook of Experimental Pharmacology 2011; 204: 167-92.
166. Bollen E, Prickaerts J. Phosphodiesterases in neurodegenerative disorders. IUBMB Life 2012; 64: 965-970.